Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

Devine, Steven M.; Bartholomew, Amelia; Mahmud, Nadim; Nelson, Mary C.; Patil, Sheila; Hardy, Wayne; Sturgeon, Cord; Hewett, Terry A.; Chung, Theodore D.; Stock, Wendy; Sher, Dorie; Weissman, Scott M.; Ferrer, Karen; Mosca, Joseph D.; Deans, Robert; Moseley, Annemarie; Hoffman, Ronald

doi:10.1016/s0301-472x(00)00635-4

Cited by 395 publications

(291 citation statements)

References 49 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…7 In baboons receiving labeled MSCs, cells were still detected in the bone marrow for more than 500 days posttransplantation. 20 Moreover, GFP-labeled cells were not detected in other tissues despite the use of a sensitive PCR technique, suggesting that MSCs home preferentially to the bone marrow. Following intracerebral implantation, MSCs were able to proliferate, differentiate and appeared to migrate along the well-defined neural migration pathways.…”

Section: Tissue-homing Capacities Of Mscsmentioning

confidence: 99%

Engineering mesenchymal stem cells for immunotherapy

et al. 2003

View full text Add to dashboard Cite

Section: Tissue-homing Capacities Of Mscsmentioning

confidence: 99%

Engineering mesenchymal stem cells for immunotherapy

et al. 2003

View full text Add to dashboard Cite

“…Infusion of BM-derived osteoblasts promoted the engraftment of allogeneic hematopoietic stem cells in mice. 29 Other studies in non-obese diabetic/severely compromised immunodeficient mice indicate that co-transplantation of MSCs and cord blood enhances engraftment of human hematopoietic cells in the BM of non-obese diabetic/ severely compromised immunodeficient mice. 30 Co-infusion of fetal lung-derived MSCs and umbilical cord bloodderived CD34 þ cells promoted the engraftment of both myeloid and B lymphoid cells in the marrow of recipient mice, showing that the engraftment-promoting effect of MSCs was not lineage specific.…”

Section: Preclinical Resultsmentioning

confidence: 98%

Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT

Ball

Bernardo

Locatelli

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

“…38 Several other investigators have reported similar findings in murine, sheep and baboon animal models. [39][40][41][42] Using similar approaches as above but with bettercharacterized mouse bone marrow stromal cells, the current authors have shown that cells infused into mouse femurs persist in bone. Murine adherent marrow stromal cells were established using standard methods and were then marked by transduction with a retrovirus carrying the LacZ marker gene.…”

Section: Cell Therapymentioning

confidence: 87%

Gene therapy approaches for osteogenesis imperfecta

et al. 2004

View full text Add to dashboard Cite

Osteogenesis imperfecta (OI) is a heterogeneous group of genetic disorders that affect connective tissue integrity. The hallmark of OI is bone fragility, although other manifestations, which include osteoporosis, dentigenesis imperfecta, blue sclera, easy bruising, joint laxity and scoliosis, are also common among OI patients. The severity of OI ranges from prenatal death to mild osteopenia without limb deformity. Most forms of OI result from mutations in the genes that encode either the proa1or proa2 polypeptide chains that comprise type I collagen molecules, the major structural protein of bone. Treatment depends mainly on the severity of the disease with the primary goal to minimize fractures and maximize function. Current treatments include surgical intervention with intramedullarly stabilization and the use of prostheses. Pharmacological agents have also been attempted with limited success with the exception of recent use of bisphosphonates, which have been to shown to have some effect. Since OI is a genetic disease, these agents are not expected to alter the course of the collagen mutations. Cell and gene therapies as potential treatments for OI are therefore currently being actively investigated. The design of gene therapies for OI is however complicated by the genetic heterogeneity of the disease and by the factor that most of the OI mutations are dominant negative where the mutant allele product interferes with the function of the normal allele. The present review will discuss the molecular changes seen in OI, the current treatment options and the gene therapy approaches being investigated as potential future treatments for OI.

show abstract

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

Cited by 395 publications

References 49 publications

Engineering mesenchymal stem cells for immunotherapy

Engineering mesenchymal stem cells for immunotherapy

Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT

Gene therapy approaches for osteogenesis imperfecta

Contact Info

Product

Resources

About